The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

FDA Regenerative Medicine Advanced Therapy designation for P-BCMA CAR T-cell therapy

Nov 20, 2018

The US Food and Drug Administration (FDA) has granted the P-BCMA-101 CAR T-cell therapy the Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of relapsed/refractory multiple myeloma (MM). The decision was based on preliminary resultsof a phase I clinical trial, whose primary outcome is to define the maximum tolerated dose of P-BCMA-101 based on dose-limiting toxicities.

P-BCMA-101 is an autologous CAR T-cell product, which targets the BCMA (B-cell maturation antigen), a protein highly expressed on the cell surface of MM cells. The RMAT designationis authorized for a drug that is defined as a cell therapy, intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition, and which is supported by preliminary clinical evidence indicating that it has the potential to address unmet medical needs for such a disease or condition.

The RMAT process allows companies to develop regenerative medicine therapies (including cell therapies) and interact with the US FDA frequently and at a very early stage of a clinical trial. RMAT-products may be granted priority review and accelerated approval.

  1. Myeloma Research News online. FDA Grants Poseida’s P-BCMA-101 RMAT Status for Treatment of Multiple Myeloma. [Accessed November 20 2018].
  2. Globenewswire online. Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-101. [Accessed November 20 2018].